Supplementary material to article by G. Yosipovitch et al. “Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis”

Fig. S2. Sensitivity analysis of relative contribution of itch and Psoriasis Area and Severity Index (PASI) scores on change in Dermatology Life Quality Index (DLQI) total score without symptoms and feelings domain score at Week 4 and Week 12. ETN: etanercept; IXE Q2W: ixekizumab 80 mg once every 2 weeks; IXE Q4W: ixekizumab 80 mg once every 4 weeks; PBO: placebo.